In a May 2026 market update1 prepared for Stifel Healthcare Investment Banking, Managing Director Tim Opler traveled to Shanghai and Beijing the week of June 8 to gather ground-level impressions from biotechs, pharmaceutical companies, and investors. What he found was a sector moving with a speed and ambition that Western observers are still struggling to fully absorb.
The thesis, stated plainly: "China is playing for keeps and is a country that is investing heavily in capabilities and technologies to better serve its people, with the view that relying on the West for technology and resource access is not wise."
A Country Obsessed With Engineering
Opler frames China's foundational advantage not as deep scientific discovery, but as engineering excellence at scale. "China continues to excel in delivering low-cost solutions to high tech problems with very fast cycle times," he writes, conceding almost as an afterthought that "in some ways, it's not so bad to go second."
That framing is changing, however. First-in-class pharmaceutical innovation is becoming more common in China. Opler's team encountered companies pursuing novel receptor targets beyond NAV1.8 for treating serious pain, working from first principles on the genetics of pain. Another company has generated "quite solid Phase 2 data" for a radically new approach to the dry form of AMD. The creativity is extending beyond oncology and autoimmune to diseases like sickle cell, where Chinese companies are now in the clinic with in vivo cell engineering. "Pretty amazing to see," Opler notes.
Industrial Hyperproliferation
The growth in certain therapeutic categories strains comprehension. There are now over 25 Chinese companies working on RNAi therapeutics, with manufacturing unit costs via CDMOs running in the $150 to $300 range, "well below ranges in the West." In in vivo CAR-T, the count has gone from roughly 100 companies last autumn to over 300 today, with more than 100 having achieved clinical data through investigator-initiated trials. The China Biotech Park area in Beijing's outskirts covers at least as much acreage as South San Francisco and represents only one of at least five distinct biotech parks in Beijing.
Opler's caution is warranted: "most of these companies will not be able to survive," and several have been running into major liver and kidney toxicity events in their investigator-initiated studies.
The Deal Flow Has Already Shifted
The licensing data is the piece of the report that should command the most attention from advisors and investors. Through June 13, 2026, roughly half of all large pharma licensing deals of $50 million or more upfront have been sourced from China, up from zero in 2019. More striking still: when measured by total dollars and equity paid, 68% of all biopharma license deal value in 2026 has gone to Chinese counterparties.
The numbers behind this shift are significant. Total upfront dollars paid by big pharma for China licensing deals in the first 24 weeks of 2026 reached $4.5 billion, compared to $5.1 billion for all of 2025 and $12.9 billion across the entire 2019 to 2025 period combined. This has been driven in part by large portfolio R&D arrangements: AstraZeneca with CSPC ($1.2 billion upfront for eight metabolic programs), BMS with Hengrui ($950 million for thirteen programs), Pfizer with Innovent ($650 million for twelve programs), and Lilly with Innovent ($350 million for antibody work).
At dinner with a senior representative of one of these large pharmas, Opler is told directly that "the Chinese leverage in building early pipeline was unbeatable compared to the costs, timelines, politics and bureaucracy found back in their U.S. pharma organizations." The goal, as Opler notes, "isn't to shrink R&D back home but rather to grow the pipeline and get more results per R&D dollar."
The Friction Points
None of this is without complication. The Hang Seng Biotech Index is down over 30% from last September. There are roughly 500 companies in the queue to go public in Hong Kong, and Chinese institutions and retail buyers cannot absorb the supply. The market has created "a bit of a liquidity desert for many companies." Companies like 3SBio have seen their market cap halved since last September, with observers noting that the current capitalized value does not match the proceeds from the Pfizer deal, let alone the rest of the platform.
On the geopolitical side, U.S. Congressional measures targeting Chinese pharmaceutical innovation are seen by executives in China as "largely political grandstanding" that "would likely come at more of a cost to U.S. patients than to Chinese wallets." The frustration cuts both ways: Chinese CEOs are increasingly vocal about what they perceive as a tacit bias in how Western conferences evaluate Chinese clinical data, pointing specifically to commentary on Akeso's PD1 x VEGF results at ASCO.
The single most compelling observation from the trip, however, comes not from the deal data but from a CEO Opler interviewed directly. Asked what is truly different in China biotech in 2026 versus 2025, the answer is unambiguous: "what is really changing is the quality of the human capital." Good biotech talent, the CEO says, "is far more available now than just a year ago and this is contributing to more risk-taking and higher quality programs across the industry."
5 Key Takeaways for Advisors and Investors
- China's share of large pharma licensing is structural, not cyclical. At 50% of deal count and 68% of deal dollars in 2026, Chinese counterparties have become the dominant source of pipeline for global pharma. This trend is accelerating, not plateauing.
- Portfolio R&D deals represent a new category of risk and opportunity. Arrangements where big pharma pays billions upfront to co-develop large early-stage pipelines with Chinese firms are a materially different risk profile than single-asset licensing. Investors in large pharma companies should understand how much early pipeline is now being built offshore.
- The HKEX biotech discount is real and deepening. With 500 companies queued for IPO and the index down 30%, valuations of listed Chinese biotechs can diverge dramatically from underlying deal value. Opler's example of 3SBio is illustrative of a broader dislocation.
- Manufacturing cost advantages in modalities like RNAi are not temporary. CDMOs in China are now producing RNAi therapies at $150 to $300 per unit, well below Western equivalents. This cost structure shapes competitive dynamics for any company developing these therapies globally.
- Human capital quality is the variable that changes the long-term calculus. The upgrade in talent availability Opler describes is not a data point but a structural shift. When the talent base deepens, innovation compounds. The implication for global biotech competitive positioning is significant and not yet fully priced.
Footnote:
1 Opler, Tim. "China Biotech: Evolving at Lightning Speed." Stifel Healthcare Investment Banking, May 2026, https://www.stifel.com/newsletters/investmentbanking/bal/marketing/healthcare/biopharma_timopler/2026/BiopharmaMarketUpdate_061526.pdf. Accessed 23 Oct. 2026.
